Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Almudena Tercero"'
Autor:
Jing Yang, Jason D. Lickliter, Jan L. Hillson, Gary D. Means, Russell J. Sanderson, Kay Carley, Almudena Tercero, Kristi L. Manjarrez, Jennifer R. Wiley, Stanford L. Peng
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)
Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator
Externí odkaz:
https://doaj.org/article/701f4101ee394f428fca2532c07f1b57
Autor:
Almudena Tercero, Dan Finlay, Liya H Asghedom, Gladys R Romasanta, Natalie T Rice, Fatima Ranjbaran, Carrie Stoltzman, Jody Cook, Joe Blake, Colleen Delaney, Joshua A Hill
Publikováno v:
Stem Cells Translational Medicine. 11:S12-S12
Introduction In the setting of viral infections, including infection with SARS-CoV-2, lymphocyte exhaustion and lymphopenia are common. Patients with COVID-19 who develop lymphopenia, particularly low numbers of circulating natural killer (NK) cells,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::580ae2de0cb0f020464cc99ee6d03247
https://doi.org/10.1093/stcltm/szac057.010
https://doi.org/10.1093/stcltm/szac057.010
Autor:
Jennifer R. Wiley, Jing Yang, Gary Means, Stanford L. Peng, Jason D. Lickliter, Kay Carley, Russell J. Sanderson, Jan Hillson, Kristi Manjarrez, Almudena Tercero
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)
ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061513295bba9dfd47595f6cac8f4cdf
https://pubmed.ncbi.nlm.nih.gov/33503289
https://pubmed.ncbi.nlm.nih.gov/33503289
Autor:
Wael A. Harb, Jing Yang, Diwakar Davar, Justin C. Moser, Gary Means, Hany Zayed, Almudena Tercero, Kristi Manjarrez, Stanford L. Peng, Graciela Noemi Perez, Jan Hillson, Christine Dela Cruz, Michael Millward, Mark Voskoboynik, Nehal Lakhani
Publikováno v:
Cancer Research. 81:CT213-CT213
BACKGROUND: Checkpoint inhibitors (CPI) targeting the PD-1 and CTLA-4 pathways have demonstrated significant clinical benefit in multiple tumors, but the majority of patients exhibit or develop resistance, at least in part due to insufficient activat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09811f595a6032d6479237e1b4bee1ee
https://doi.org/10.1158/1538-7445.am2021-ct213
https://doi.org/10.1158/1538-7445.am2021-ct213
Publikováno v:
Cancer Research. 80:CT245-CT245
Background: Checkpoint inhibitors (CPI) targeting the PD-(L)1 and CTLA-4 pathways have demonstrated significant clinical benefit in many cancers, but the majority of patients unfortunately still fail to demonstrate objective responses and/or develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ecf37b134c795958f5192d452543151
https://doi.org/10.1158/1538-7445.am2020-ct245
https://doi.org/10.1158/1538-7445.am2020-ct245
Autor:
Jing Yang, Mark Voskoboynik, Justin C. Moser, Diwakar Davar, Michael Millward, Christine Dela Cruz, Kristi Manjarrez, Stanford L. Peng, Wael A. Harb, Graciela Noemi Perez, Jan Hillson, Gary Means, Nehal Lakhani, Almudena Tercero, Hany Zayed
Publikováno v:
Journal of Clinical Oncology. 39:2547-2547
2547 Background: Strong preclinical rationale has emerged for combining checkpoint inhibition (CPI) with T cell costimulatory agonists, particularly CD28, a critical T cell costimulatory molecule recently recognized as a key target of checkpoint inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2737c48b24bfcdce0bfc6e46faee3a03
https://doi.org/10.1200/jco.2021.39.15_suppl.2547
https://doi.org/10.1200/jco.2021.39.15_suppl.2547
Autor:
Yang, Jing1 (AUTHOR) jing.yang@alpineimmunesciences.com, Lickliter, Jason D.2 (AUTHOR), Hillson, Jan L.1 (AUTHOR), Means, Gary D.1 (AUTHOR), Sanderson, Russell J.1 (AUTHOR), Carley, Kay1 (AUTHOR), Tercero, Almudena1 (AUTHOR), Manjarrez, Kristi L.1 (AUTHOR), Wiley, Jennifer R.1 (AUTHOR), Peng, Stanford L.1 (AUTHOR)
Publikováno v:
CTS: Clinical & Translational Science. Jul2021, Vol. 14 Issue 4, p1314-1326. 13p.
Autor:
G. Means, J. Yang, K. Carley, J. Lickliter, J. Hillson, S. L. Peng, A. Tercero, K. Manjarrez, J. Wiley, R. Sanderson
Publikováno v:
Annals of the Rheumatic Diseases. 79:1040-1040
Background:ALPN-101 (ICOSL vIgD-Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD™) designed to inhibit simultaneously the CD28 and ICOS inflammation pathways (1). ALPN-101 is e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40775bb80ffd371ffeecceaa0ed25e9
https://doi.org/10.1136/annrheumdis-2020-eular.2388
https://doi.org/10.1136/annrheumdis-2020-eular.2388